ORPP logo
Image from Google Jackets

Cardiovascular Diseases : From Molecular Pharmacology to Evidence-Based Therapeutics.

By: Material type: TextTextSeries: New York Academy of Sciences SeriesPublisher: Newark : John Wiley & Sons, Incorporated, 2015Copyright date: ©2015Edition: 1st edDescription: 1 online resource (504 pages)Content type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9781118889947
Subject(s): Genre/Form: Additional physical formats: Print version:: Cardiovascular DiseasesDDC classification:
  • 616.1/061
LOC classification:
  • RC669 .L5 2015
Online resources:
Contents:
Intro -- Title Page -- Copyright Page -- Contents -- Preface -- List of Abbreviations -- Unit I General Introduction -- Chapter 1 Introduction to Cardiovascular Diseases -- 1.1 Overview -- 1.2 Definition of Cardiovascular Diseases -- 1.3 Classification of Cardiovascular Diseases -- 1.3.1 Classification Based on Anatomical Location -- 1.3.2 Classification Based on the Involvement of Atherosclerosis -- 1.3.3 Total Cardiovascular Diseases and ICD-10 Classification -- 1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases -- 1.4.1 NCDs and Cardiovascular Diseases: The Global Status -- 1.4.2 The Status of Cardiovascular Diseases in the United States -- 1.4.3 The Status of Cardiovascular Diseases in China -- 1.5 Risk Factors of Cardiovascular Diseases -- 1.5.1 Classification of Cardiovascular Disease Risk Factors -- 1.5.2 Major Cardiovascular Disease Risk Factors and Their Impact -- 1.6 Prevention and Control of Cardiovascular Diseases -- 1.6.1 The UN High-Level Meeting and Tackling Cardiovascular Diseases at the Global Level -- 1.6.2 The World Heart Federation Call to Action to Prevent and Control Cardiovascular Diseases -- 1.6.3 The AHA 2010 Health Impact Goal, 2020 Health Impact Goal, and Ideal Cardiovascular Health -- 1.6.4 US DHSS "Million Hearts" Initiative -- 1.7 Cardiovascular Risk Prediction and Evidence-based Treatments -- 1.7.1 Cardiovascular Risk Prediction -- 1.7.2 Evidence-Based Treatments -- 1.8 Summary of Chapter Key Points -- 1.9 Self-Assessment Questions -- References -- Chapter 2 Introduction to Principles of Pharmacology -- 2.1 Overview -- 2.2 Definitions and History -- 2.2.1 What Is Pharmacology? -- 2.2.2 Definitions of Related Terms -- 2.2.3 A Brief History of Pharmacology -- 2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology -- 2.3.1 Drug Names, Sources, Preparations, and Administration.
2.3.2 Pharmacokinetics -- 2.3.3 Pharmacodynamics -- 2.3.4 Drug Toxicity -- 2.3.5 Pharmacogenetics and Pharmacogenomics -- 2.4 Principles of Drug Discovery, Development, and Regulation -- 2.4.1 Definitions -- 2.4.2 The Paradigm of Drug Creation and Survival -- 2.4.3 The FDA Drug Review and Approval Process -- 2.5 Pharmacology Subspecialties -- 2.6 Introduction to Cardiovascular Pharmacology -- 2.6.1 Definition and Scope -- 2.6.2 New Developments and Challenges -- 2.6.3 Systems Pharmacology in the Management of Cardiovascular Diseases -- 2.6.4 Polypill for the Management of Cardiovascular Diseases -- 2.6.5 Protein Therapeutics of Cardiovascular Diseases -- 2.6.6 Gene Therapy of Cardiovascular Diseases -- 2.6.7 Stem Cell Therapy of Cardiovascular Diseases -- 2.7 Summary of Chapter Key Points -- 2.8 Self-Assessment Questions -- References -- Unit II Dyslipidemias -- Chapter 3 Overview of Dyslipidemias and Drug Therapy -- 3.1 Introduction -- 3.2 Lipoprotein Metabolism -- 3.2.1 Definition, Structure, and Classification of Lipoproteins -- 3.2.2 Metabolic Pathways of Lipoproteins and Drug Therapy -- 3.3 Dyslipidemias and Genetic Lipoprotein Disorders -- 3.3.1 Classification and Molecular Etiologies -- 3.3.2 The Four Types of Dyslipidemias and Their Underlying Genetic Lipoprotein Disorders -- 3.4 Mechanistically Based Drug Therapy of Dyslipidemias -- 3.5 Summary of Chapter Key Points -- 3.6 Self-Assessment Questions -- References -- Chapter 4 Drugs for Dyslipidemias -- 4.1 Overview -- 4.2 Statins -- 4.2.1 General Introduction to Drug Class -- 4.2.2 Chemistry and Pharmacokinetics -- 4.2.3 Molecular Mechanisms and Pharmacological Effects -- 4.2.4 Clinical Uses -- 4.2.5 Therapeutic Dosages -- 4.2.6 Adverse Effects and Drug Interactions -- 4.2.7 Summary of Statin Drugs -- 4.3 Bile Acid Sequestrants -- 4.3.1 General Introduction to Drug Class.
4.3.2 Chemistry and Pharmacokinetics -- 4.3.3 Molecular Mechanisms and Pharmacological Effects -- 4.3.4 Clinical Uses -- 4.3.5 Therapeutic Dosages -- 4.3.6 Adverse Effects and Drug Interactions -- 4.3.7 Summary of Bile Acid Sequestrants -- 4.4 Cholesterol Absorption Inhibitors -- 4.4.1 General Introduction to Drug Class -- 4.4.2 Chemistry and Pharmacokinetics -- 4.4.3 Molecular Mechanisms and Pharmacological Effects -- 4.4.4 Clinical Uses -- 4.4.5 Therapeutic Dosages -- 4.4.6 Adverse Effects and Drug Interactions -- 4.4.7 Summary of Ezetimibe -- 4.5 Fibrates -- 4.5.1 General Introduction to Drug Class -- 4.5.2 Chemistry and Pharmacokinetics -- 4.5.3 Molecular Mechanisms and Pharmacological Effects -- 4.5.4 Clinical Uses -- 4.5.5 Therapeutic Dosages -- 4.5.6 Adverse Effects and Drug Interactions -- 4.5.7 Summary of Fibrates -- 4.6 Niacin -- 4.6.1 General Introduction to Niacin -- 4.6.2 Chemistry and Pharmacokinetics -- 4.6.3 Molecular Mechanisms and Pharmacological Effects -- 4.6.4 Clinical Uses -- 4.6.5 Therapeutic Dosages -- 4.6.6 Adverse Effects and Drug Interactions -- 4.6.7 Summary of Niacin -- 4.7 New Drugs for HoFH -- 4.7.1 Lomitapide -- 4.7.2 Mipomersen -- 4.7.3 Summary of New Drugs for HoFH -- 4.8 Phytosterols and Phytostanols -- 4.8.1 Introduction to Phytosterols and Phytostanols -- 4.8.2 Molecular Mechanisms and Pharmacological Effects -- 4.8.3 Clinical Uses -- 4.8.4 Therapeutic Dosages -- 4.8.5 Adverse Effects and Drug Interactions -- 4.8.6 Summary of Phytosterols/Phytostanols -- 4.9 Omega-3 Fatty Acids -- 4.9.1 Introduction to Omega-3 Fatty Acids -- 4.9.2 Molecular Mechanisms and Pharmacological Effects -- 4.9.3 Clinical Uses -- 4.9.4 Therapeutic Dosages -- 4.9.5 Adverse Effects and Drug Interactions -- 4.9.6 Summary of Omega-3 Fatty Acids -- 4.10 Emerging Therapeutic Modalities for Dyslipidemias.
4.10.1 Emerging Therapeutic Strategies Targeting LDL -- 4.10.2 Novel Therapeutic Strategies Targeting HDL -- 4.10.3 Summary of Emerging Drugs -- 4.11 Summary of Chapter Key Points -- 4.12 Self-Assessment Questions -- References -- Chapter 5 Management of Dyslipidemias: Principles and Guidelines -- 5.1 Overview -- 5.2 General Principles of the Management of Dyslipidemias -- 5.2.1 Defining Dyslipidemias in the Context of Disease Management -- 5.2.2 Understanding Laboratory Lipid Profiles -- 5.2.3 Cardiovascular Risk Assessment -- 5.2.4 Treatment Goals -- 5.2.5 General Approaches to Management: Lifestyle Modifications and Drug Therapies -- 5.2.6 Management in Specific Clinical Settings -- 5.2.7 Treatment Monitoring and Adherence -- 5.3 Current Evidence-Based Guidelines on the Management of Dyslipidemias -- 5.3.1 Defining Clinical Guidelines in the Context of Dyslipidemia Management -- 5.3.2 Classification of Evidence-Based Guideline Recommendations and Strength of Evidence -- 5.3.3 Current Guidelines on the Management of Dyslipidemias -- 5.3.4 Comparison and Contrast of Current Lipid Guidelines -- 5.4 Summary of Chapter Key Points -- 5.5 Self-Assessment Questions -- References -- Unit III Hypertension and Multitasking Cardiovascular Drugs -- Chapter 6 Overview of Hypertension and Drug Therapy -- 6.1 Introduction -- 6.2 Definitions, Classifications, and Epidemiology of Hypertension -- 6.2.1 Definitions and Classifications -- 6.2.2 Epidemiology and Health Impact of Hypertension -- 6.3 Pathophysiology of Hypertension -- 6.3.1 Physiology of Blood Pressure Regulation -- 6.3.2 Molecular Pathophysiology of Hypertension Development -- 6.4 Mechanistically Based Drug Therapy of Hypertension: An Overview -- 6.4.1 Historical Overview -- 6.4.2 Mechanistic Overview -- 6.5 Summary of Chapter Key Points -- 6.6 Self-Assessment Questions -- References.
Chapter 7 Diuretics -- 7.1 Overview -- 7.2 Volume Regulation and Drug Targeting -- 7.2.1 Renal Physiology and Volume Regulation -- 7.2.2 Drug Class and Drug Targeting -- 7.3 Thiazide and Thiazide-Type Diuretics -- 7.3.1 General Introduction to Drug Class -- 7.3.2 Chemistry and Pharmacokinetics -- 7.3.3 Molecular Mechanisms and Pharmacological Effects -- 7.3.4 Clinical Uses -- 7.3.5 Therapeutic Dosages in Cardiovascular Applications -- 7.3.6 Adverse Effects and Drug Interactions -- 7.3.7 Summary of Thiazide and Thiazide-Type Diuretics -- 7.4 Loop Diuretics -- 7.4.1 General Introduction to Drug Class -- 7.4.2 Chemistry and Pharmacokinetics -- 7.4.3 Molecular Mechanisms and Pharmacological Effects -- 7.4.4 Clinical Uses -- 7.4.5 Therapeutic Dosages in Heart Failure Treatment -- 7.4.6 Adverse Effects and Drug Interactions -- 7.4.7 Summary of Loop Diuretics -- 7.5 Potassium-Sparing Diuretics -- 7.5.1 General Introduction to Drug Class -- 7.5.2 Chemistry and Pharmacokinetics -- 7.5.3 Molecular Mechanisms and Pharmacological Effects -- 7.5.4 Clinical Uses -- 7.5.5 Therapeutic Dosages -- 7.5.6 Adverse Effects and Drug Interactions -- 7.6 Other Diuretics -- 7.7 Summary of Chapter Key Points -- 7.8 Self-Assessment Questions -- References -- Chapter 8 Sympatholytics -- 8.1 Overview -- 8.2 Sympathetic Nervous System and Drug Targeting -- 8.2.1 Basic Divisions of the Nervous System -- 8.2.2 Sympathetic Nervous System and Cardiovascular Diseases -- 8.2.3 Drug Class and Drug Targeting -- 8.3 α-Adrenergic Receptor Antagonists -- 8.4 β-Adrenergic Receptor Antagonists -- 8.4.1 General Introduction to Drug Class -- 8.4.2 Chemistry and Pharmacokinetics -- 8.4.3 Molecular Mechanisms and Pharmacological Effects -- 8.4.4 Clinical Uses -- 8.4.5 Dosage Forms and Strengths -- 8.4.6 Adverse Effects and Drug Interactions -- 8.5 Centrally Acting Sympatholytics.
8.6 Summary of Chapter Key Points.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Intro -- Title Page -- Copyright Page -- Contents -- Preface -- List of Abbreviations -- Unit I General Introduction -- Chapter 1 Introduction to Cardiovascular Diseases -- 1.1 Overview -- 1.2 Definition of Cardiovascular Diseases -- 1.3 Classification of Cardiovascular Diseases -- 1.3.1 Classification Based on Anatomical Location -- 1.3.2 Classification Based on the Involvement of Atherosclerosis -- 1.3.3 Total Cardiovascular Diseases and ICD-10 Classification -- 1.4 Prevalence, Incidence, and Trend of Cardiovascular Diseases -- 1.4.1 NCDs and Cardiovascular Diseases: The Global Status -- 1.4.2 The Status of Cardiovascular Diseases in the United States -- 1.4.3 The Status of Cardiovascular Diseases in China -- 1.5 Risk Factors of Cardiovascular Diseases -- 1.5.1 Classification of Cardiovascular Disease Risk Factors -- 1.5.2 Major Cardiovascular Disease Risk Factors and Their Impact -- 1.6 Prevention and Control of Cardiovascular Diseases -- 1.6.1 The UN High-Level Meeting and Tackling Cardiovascular Diseases at the Global Level -- 1.6.2 The World Heart Federation Call to Action to Prevent and Control Cardiovascular Diseases -- 1.6.3 The AHA 2010 Health Impact Goal, 2020 Health Impact Goal, and Ideal Cardiovascular Health -- 1.6.4 US DHSS "Million Hearts" Initiative -- 1.7 Cardiovascular Risk Prediction and Evidence-based Treatments -- 1.7.1 Cardiovascular Risk Prediction -- 1.7.2 Evidence-Based Treatments -- 1.8 Summary of Chapter Key Points -- 1.9 Self-Assessment Questions -- References -- Chapter 2 Introduction to Principles of Pharmacology -- 2.1 Overview -- 2.2 Definitions and History -- 2.2.1 What Is Pharmacology? -- 2.2.2 Definitions of Related Terms -- 2.2.3 A Brief History of Pharmacology -- 2.3 Pharmacological Paradigm: the Central Dogma in Pharmacology -- 2.3.1 Drug Names, Sources, Preparations, and Administration.

2.3.2 Pharmacokinetics -- 2.3.3 Pharmacodynamics -- 2.3.4 Drug Toxicity -- 2.3.5 Pharmacogenetics and Pharmacogenomics -- 2.4 Principles of Drug Discovery, Development, and Regulation -- 2.4.1 Definitions -- 2.4.2 The Paradigm of Drug Creation and Survival -- 2.4.3 The FDA Drug Review and Approval Process -- 2.5 Pharmacology Subspecialties -- 2.6 Introduction to Cardiovascular Pharmacology -- 2.6.1 Definition and Scope -- 2.6.2 New Developments and Challenges -- 2.6.3 Systems Pharmacology in the Management of Cardiovascular Diseases -- 2.6.4 Polypill for the Management of Cardiovascular Diseases -- 2.6.5 Protein Therapeutics of Cardiovascular Diseases -- 2.6.6 Gene Therapy of Cardiovascular Diseases -- 2.6.7 Stem Cell Therapy of Cardiovascular Diseases -- 2.7 Summary of Chapter Key Points -- 2.8 Self-Assessment Questions -- References -- Unit II Dyslipidemias -- Chapter 3 Overview of Dyslipidemias and Drug Therapy -- 3.1 Introduction -- 3.2 Lipoprotein Metabolism -- 3.2.1 Definition, Structure, and Classification of Lipoproteins -- 3.2.2 Metabolic Pathways of Lipoproteins and Drug Therapy -- 3.3 Dyslipidemias and Genetic Lipoprotein Disorders -- 3.3.1 Classification and Molecular Etiologies -- 3.3.2 The Four Types of Dyslipidemias and Their Underlying Genetic Lipoprotein Disorders -- 3.4 Mechanistically Based Drug Therapy of Dyslipidemias -- 3.5 Summary of Chapter Key Points -- 3.6 Self-Assessment Questions -- References -- Chapter 4 Drugs for Dyslipidemias -- 4.1 Overview -- 4.2 Statins -- 4.2.1 General Introduction to Drug Class -- 4.2.2 Chemistry and Pharmacokinetics -- 4.2.3 Molecular Mechanisms and Pharmacological Effects -- 4.2.4 Clinical Uses -- 4.2.5 Therapeutic Dosages -- 4.2.6 Adverse Effects and Drug Interactions -- 4.2.7 Summary of Statin Drugs -- 4.3 Bile Acid Sequestrants -- 4.3.1 General Introduction to Drug Class.

4.3.2 Chemistry and Pharmacokinetics -- 4.3.3 Molecular Mechanisms and Pharmacological Effects -- 4.3.4 Clinical Uses -- 4.3.5 Therapeutic Dosages -- 4.3.6 Adverse Effects and Drug Interactions -- 4.3.7 Summary of Bile Acid Sequestrants -- 4.4 Cholesterol Absorption Inhibitors -- 4.4.1 General Introduction to Drug Class -- 4.4.2 Chemistry and Pharmacokinetics -- 4.4.3 Molecular Mechanisms and Pharmacological Effects -- 4.4.4 Clinical Uses -- 4.4.5 Therapeutic Dosages -- 4.4.6 Adverse Effects and Drug Interactions -- 4.4.7 Summary of Ezetimibe -- 4.5 Fibrates -- 4.5.1 General Introduction to Drug Class -- 4.5.2 Chemistry and Pharmacokinetics -- 4.5.3 Molecular Mechanisms and Pharmacological Effects -- 4.5.4 Clinical Uses -- 4.5.5 Therapeutic Dosages -- 4.5.6 Adverse Effects and Drug Interactions -- 4.5.7 Summary of Fibrates -- 4.6 Niacin -- 4.6.1 General Introduction to Niacin -- 4.6.2 Chemistry and Pharmacokinetics -- 4.6.3 Molecular Mechanisms and Pharmacological Effects -- 4.6.4 Clinical Uses -- 4.6.5 Therapeutic Dosages -- 4.6.6 Adverse Effects and Drug Interactions -- 4.6.7 Summary of Niacin -- 4.7 New Drugs for HoFH -- 4.7.1 Lomitapide -- 4.7.2 Mipomersen -- 4.7.3 Summary of New Drugs for HoFH -- 4.8 Phytosterols and Phytostanols -- 4.8.1 Introduction to Phytosterols and Phytostanols -- 4.8.2 Molecular Mechanisms and Pharmacological Effects -- 4.8.3 Clinical Uses -- 4.8.4 Therapeutic Dosages -- 4.8.5 Adverse Effects and Drug Interactions -- 4.8.6 Summary of Phytosterols/Phytostanols -- 4.9 Omega-3 Fatty Acids -- 4.9.1 Introduction to Omega-3 Fatty Acids -- 4.9.2 Molecular Mechanisms and Pharmacological Effects -- 4.9.3 Clinical Uses -- 4.9.4 Therapeutic Dosages -- 4.9.5 Adverse Effects and Drug Interactions -- 4.9.6 Summary of Omega-3 Fatty Acids -- 4.10 Emerging Therapeutic Modalities for Dyslipidemias.

4.10.1 Emerging Therapeutic Strategies Targeting LDL -- 4.10.2 Novel Therapeutic Strategies Targeting HDL -- 4.10.3 Summary of Emerging Drugs -- 4.11 Summary of Chapter Key Points -- 4.12 Self-Assessment Questions -- References -- Chapter 5 Management of Dyslipidemias: Principles and Guidelines -- 5.1 Overview -- 5.2 General Principles of the Management of Dyslipidemias -- 5.2.1 Defining Dyslipidemias in the Context of Disease Management -- 5.2.2 Understanding Laboratory Lipid Profiles -- 5.2.3 Cardiovascular Risk Assessment -- 5.2.4 Treatment Goals -- 5.2.5 General Approaches to Management: Lifestyle Modifications and Drug Therapies -- 5.2.6 Management in Specific Clinical Settings -- 5.2.7 Treatment Monitoring and Adherence -- 5.3 Current Evidence-Based Guidelines on the Management of Dyslipidemias -- 5.3.1 Defining Clinical Guidelines in the Context of Dyslipidemia Management -- 5.3.2 Classification of Evidence-Based Guideline Recommendations and Strength of Evidence -- 5.3.3 Current Guidelines on the Management of Dyslipidemias -- 5.3.4 Comparison and Contrast of Current Lipid Guidelines -- 5.4 Summary of Chapter Key Points -- 5.5 Self-Assessment Questions -- References -- Unit III Hypertension and Multitasking Cardiovascular Drugs -- Chapter 6 Overview of Hypertension and Drug Therapy -- 6.1 Introduction -- 6.2 Definitions, Classifications, and Epidemiology of Hypertension -- 6.2.1 Definitions and Classifications -- 6.2.2 Epidemiology and Health Impact of Hypertension -- 6.3 Pathophysiology of Hypertension -- 6.3.1 Physiology of Blood Pressure Regulation -- 6.3.2 Molecular Pathophysiology of Hypertension Development -- 6.4 Mechanistically Based Drug Therapy of Hypertension: An Overview -- 6.4.1 Historical Overview -- 6.4.2 Mechanistic Overview -- 6.5 Summary of Chapter Key Points -- 6.6 Self-Assessment Questions -- References.

Chapter 7 Diuretics -- 7.1 Overview -- 7.2 Volume Regulation and Drug Targeting -- 7.2.1 Renal Physiology and Volume Regulation -- 7.2.2 Drug Class and Drug Targeting -- 7.3 Thiazide and Thiazide-Type Diuretics -- 7.3.1 General Introduction to Drug Class -- 7.3.2 Chemistry and Pharmacokinetics -- 7.3.3 Molecular Mechanisms and Pharmacological Effects -- 7.3.4 Clinical Uses -- 7.3.5 Therapeutic Dosages in Cardiovascular Applications -- 7.3.6 Adverse Effects and Drug Interactions -- 7.3.7 Summary of Thiazide and Thiazide-Type Diuretics -- 7.4 Loop Diuretics -- 7.4.1 General Introduction to Drug Class -- 7.4.2 Chemistry and Pharmacokinetics -- 7.4.3 Molecular Mechanisms and Pharmacological Effects -- 7.4.4 Clinical Uses -- 7.4.5 Therapeutic Dosages in Heart Failure Treatment -- 7.4.6 Adverse Effects and Drug Interactions -- 7.4.7 Summary of Loop Diuretics -- 7.5 Potassium-Sparing Diuretics -- 7.5.1 General Introduction to Drug Class -- 7.5.2 Chemistry and Pharmacokinetics -- 7.5.3 Molecular Mechanisms and Pharmacological Effects -- 7.5.4 Clinical Uses -- 7.5.5 Therapeutic Dosages -- 7.5.6 Adverse Effects and Drug Interactions -- 7.6 Other Diuretics -- 7.7 Summary of Chapter Key Points -- 7.8 Self-Assessment Questions -- References -- Chapter 8 Sympatholytics -- 8.1 Overview -- 8.2 Sympathetic Nervous System and Drug Targeting -- 8.2.1 Basic Divisions of the Nervous System -- 8.2.2 Sympathetic Nervous System and Cardiovascular Diseases -- 8.2.3 Drug Class and Drug Targeting -- 8.3 α-Adrenergic Receptor Antagonists -- 8.4 β-Adrenergic Receptor Antagonists -- 8.4.1 General Introduction to Drug Class -- 8.4.2 Chemistry and Pharmacokinetics -- 8.4.3 Molecular Mechanisms and Pharmacological Effects -- 8.4.4 Clinical Uses -- 8.4.5 Dosage Forms and Strengths -- 8.4.6 Adverse Effects and Drug Interactions -- 8.5 Centrally Acting Sympatholytics.

8.6 Summary of Chapter Key Points.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.

There are no comments on this title.

to post a comment.

© 2024 Resource Centre. All rights reserved.